Chronic kidney disease-associated anemia: New remedies

Current Opinion in Investigational Drugs

Volumn 11, Issue 9, 2010, Pages 1030-1038

  Del Vecchio, Lucia ^a   Cavalli, Andrea ^a   Tucci, Benedetta ^a   Locatelli, Francesco ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anemia; chronic kidney disease; erythropoietin; Hematide; iron; peginesatide

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT; CNTO 530; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRIC CARBOXYMALTOSE; FERRITIN; FERUMOXYTOL; FG 2216; FG 4592; HEMOGLOBIN; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR; IRON; IRON ISOMALTOSIDE 1000; K 7174; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINESATIDE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ERYTHROPOIESIS; ESCHERICHIA COLI; FERRITIN BLOOD LEVEL; GENE EXPRESSION; GENE THERAPY; HUMAN; HYDROXYLATION; HYPOXIA; IMMUNOGENICITY; MOLECULAR WEIGHT; NONHUMAN; REVIEW; ROOM TEMPERATURE; SINGLE DRUG DOSE; TREATMENT DURATION;

ANEMIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GENE EXPRESSION REGULATION; GENE THERAPY; HEMATINICS; HUMANS; IRON COMPOUNDS; KIDNEY; KIDNEY FAILURE, CHRONIC; PEPTIDES; RENAL INSUFFICIENCY, CHRONIC;

EID: 77956242974     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Egrie JC, Browne KJ: Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant (2001) 16(Suppl 3):3-13.
2. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J: Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant (2003) 18(2):362-369.
3. Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B: Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. J Clin Pharmacol (2010) 50(5):507-520.
4. Reigner B, Jordan P, Panier A, Glaspy J: CERA (continuous erythropoiesis receptor activator), a novel erythropoietic agent: Dose-dependent response in phase I studies. Proc Am Soc Clin Oncol (2003) 22:Abs 2943.
5. Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D, MAXIMA study investigators: Intravenous methoxy polyethylene glycol-epoetin â for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA). Lancet (2007) 370(9596):1415-1421.
6. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I et al: Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin â versus darbepoetin alfa administered monthly: A randomized comparative trial. Nephrol Dial Transplant (2010):doi:10.1093/ ndt/gfq305.
7. Locatelli F, Mann JF, Aldigier JC, Sanz Guajardo D, Schmidt R, Van Vlem B, Sulowicz W, Dougherty FC, Beyer U: C.E.R.A. safety profile: A pooled analysis in patients with chronic kidney disease. Clin Nephrol (2010) 73(2):94-103.
8. Merck & Co presents R&D program, including biologics commitment, but drops PEGylated erythropoietin biosimilar: ThePharmaletter, London, UK (2010). www.thepharmaletter.com/file/94912/merck-co-presents-rd-program- including-biologics-commitment-but-drops-pegylated-erythropoietin-biosimilar. html
9. Wang YJ, Liu YD, Chen J, Hao SJ, Hu T, Ma GH, Su ZG: Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli. Int J Pharm (2010) 386(1-2):156-164.
10. Wang YJ, Hao SJ, Liu YD, Hu T, Zhang GF, Zhang X, Qi QS, Ma GH, Su ZG: PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin. J Control Release (2010) 145(3):306-313.
11. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S: Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA (1998) 95(3):1184-1188.
12. Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E: Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood (2001) 97(12):3776-3782.
13. Fares F, Ganem S, Hajouj T, Agai E: Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin â-subunit to the coding sequence of human erythropoietin. Endocrinology (2007) 148(10):5081-5087.
14. Schriebl K, Trummer E, Lattenmayer C, Weik R, Kunert R, Müller D, Katinger H, Vorauer-Uhl K: Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expr Purif (2006) 49(2):265-275.
15. Way JC, Lauder S, Brunkhorst B, Kong SM, Qi A, Webster G, Campbell I, McKenzie S, Lan Y, Marelli B, Nguyen LA et al: Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng Des Sel (2005) 18(3):111-118.
16. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP: Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med (2005) 18(3):294-303.
17. Penno CA, Kawabe Y, Ito A, Kamihira M: Production of recombinant human erythropoietin/Fc fusion protein by genetically manipulated chickens. Transgenic Res (2010) 19(2):187-195.
18. Joung CH, Shin JY, Koo JK, Lim JJ, Wang JS, Lee SJ, Tan HK, Kim SL, Lim SM: Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein Expr Purif (2009) 68(2):137-145.
19. Coscarella A, Liddi R, Di Loreto M, Bach S, Faiella A, van der Meide PH, Mele A, De Santis R: The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine (1998) 10(12):964-969.
20. Kochendoerfer GG, Chen SY, Mao F, Cressman S, Traviglia S, Shao H, Hunter CL, Low DW, Cagle EN, Carnevali M, Gueriguian V et al: Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science (2003) 299(5608):884-887.
21. Chen SY, Cressman S, Mao F, Shao H, Low DW, Beilan HS, Cagle EN, Carnevali M, Gueriguian V, Keogh PJ, Porter H et al: Synthetic erythropoietic proteins: Tuning biological performance by site-specific polymer attachment. Chem Biol (2005) 12(3):371-383.
22. Kan C, Trzupek JD, Wu B, Wan Q, Chen G, Tan Z, Yuan Y, Danishefsky SJ: Toward homogeneous erythropoietin: Chemical synthesis of the Ala1-Gly28 glycopeptide domain by 'alanine' ligation. J Am Chem Soc (2009) 131(15):5438-5443.
23. Tan Z, Shang S, Halkina T, Yuan Y, Danishefsky SJ: Toward homogeneous erythropoietin: Non-NCL-based chemical synthesis of the GlnArg166 glycopeptide domain. J Am Chem Soc (2009) 131(15):5424-5431.
24. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ: Small peptides as potent mimetics of the protein hormone erythropoietin. Science (1996) 273(5274):458-464.
25. Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ et al: Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol (2006) 34(10):1303-1311.
26. Locatelli F, Del Vecchio L: HematideTM for the treatment of chronic kidney disease-related anemia. Expert Rev Hematol (2009) 2 (4):377-383.
27. Woodburn KW, Wilson SD, Fong KL, Schatz PJ, Ferrell T, Spainhour CB, Norton D: Chronic preclinical safety evaluation of Hematide, a PEGylated peptidic erythropoiesis stimulating agent in monkeys. Haematologica (2008) 93(9):1376-1379.
28. Woodburn KW, Schatz PJ, Fong KL, Beaumier P: Erythropoiesis equivalence, pharmacokinetics and immune response following repeat Hematide administration in cynomolgus monkeys. Int J Immunopathol Pharmacol (2010) 23(1):121-129.
29. Woodburn KW, Fan Q, Winslow S, Chen MJ, Mortensen RB, Casadevall N, Stead RB, Schatz PJ: Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol (2007) 35(8):1201-1208.
30. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU: A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med (2009) 361(19):1848-1855.
31. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM: Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood (2006) 108(6):1830-1834.
32. Besarab A, Zeig S, Geronemus R, Pergola P, Whittier F, Zabaneh R, Schiller B, Kaplan M, Levin N, Wright S, Swan S et al: Hematide, a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated with epoetin alfa (EPO). Am J Kidney Dis (2007) 49(4):Abs B30.
33. Pickering LM, Cwiertka K, Jassem J, Petera J, Pettengell R, Ramlau R, Vorlicek J, Vyzula R, Andresen C, Chang S, Duliege A-M et al: Hematide, a synthetic peptide-based erythropoiesis stimulating agent (ESA), assessed for correction of anemia in oncology patients receiving chemotherapy. Blood (2006) 108:Abs 1290.
34. Preliminary top-line results from Hematide phase 3 program for anemia in chronic renal failure patients: The Medical News Sydney, Australia (2010). www.news-medical.net/news/20100621/Preliminary-top-line-results-from-Hematide- Phase-3-program-for anemia-in-chronic-renal-failure-patients.aspx
35. Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, Achuthanandam R, Spinka-Doms T, Kwok D, Graden D, Volk A et al: CNTO 530: Molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol (2008) 134(1-2):171-180.
36. Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, Pradeep A, Bugelski PJ, Wojchowski DM: CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood (2009) 113(20):4955-4962.
37. Pérez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA, Zhou H, Yohrling J, Cohen A, Burggraaf J, Franson K et al: Pharmacokinetics and pharmacodynamics of the erythropoietin mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet (2009) 48(9):601-613.
38. Hewitson KS, Schofield CJ, Ratcliffe PJ: Hypoxia-inducible factor prolyl-hydroxylase: Purification and assays of PHD2. Methods Enzymol (2007) 435:25-42.
39. Safran M, Kim WY, O'Connell F, Flippin L, Günzler V, Horner JW, Depinho RA, Kaelin WG Jr: Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA (2006) 103(1):105-110.
40. Pharma Japan: FDA permits resumption of clinical trials of FD-2216/FG-4592: Astellas. Pharma Japan (2008): April 14.
41. Dame C, Sola MC, Lim KC, Leach KM, Fandrey J, Ma Y, Knöpfle G, Engel JD, Bungert J: Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem (2004) 279(4):2955-2961.
42. Imagawa S, Yamamoto M, Miura Y: Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood (1997) 89(4):1430-1439.
43. Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, Suzuki N, Doi T, Kodama T, Takahashi S, Nagasawa T, Yamamoto M: Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood (2004) 104(13):4300-4307.
44. Sebestyén MG, Hegge JO, Noble MA, Lewis DL, Herweijer H, Wolff JA: Progress toward a nonviral gene therapy protocol for the treatment of anemia. Hum Gene Ther (2007) 18(3): 269-285.
45. Fattori E, Cappelletti M, Zampaglione I, Mennuni C, Calvaruso F, Arcuri M, Rizzuto G, Costa P, Perretta G, Ciliberto G, La Monica N: Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J Gene Med (2005) 7(2):228-236.
46. Eliopoulos N, Gagnon RF, Francois M, Galipeau J: Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol (2006) 17(6):1576-1584.
47. Oh TK, Quan GH, Kim HY, Park F, Kim ST: Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene. Am J Nephrol (2006) 26(4): 326-334.
48. Kakeda M, Hiratsuka M, Nagata K, Kuroiwa Y, Kakitani M, Katoh M, Oshimura M, Tomizuka K: Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts. Gene Ther (2005) 12(10): 852-856.
49. Gothelf A, Eriksen J, Hojman P, Gehl J: Duration and level of transgene expression after gene electrotransfer to skin in mice. Gene Ther (2010) 17(7):839-845.
50. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 361(21): 2019-2032.
51. Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C: A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol (2008) 103(5):1182-1192.
52. Gordon SS, Hadley PE, Van Wyck DB et al: Iron carboxymaltose, a new intravenous iron agent for iron deficiency anemia in heavy uterine bleeding. Obstet Gynecol (2007) 109(4 Suppl): Abs 108S.
53. Breymann C, Gliga F, Bejenariu C, Strizhova N: Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet (2008) 101(1):67-73.
54. Covic A, Mircescu G: The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: A multi-centre, open-label, clinical study. Nephrol Dial Transplant (2010) 25(8):2722-2730.
55. Grimmelt AC, Cohen CD, Fehr T, Serra AL, Wuethrich RP: Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol (2009) 71(2): 125-129.
56. Schaefer RM, Khasabov NN, Todorov NG et al: The efficacy and safety of intravenous ferric carboxymaltose compared to iron sucrose in haemodialysis patients with iron deficiency anaemia. Congress of the European Renal Association and the European Dialysis and Transplant Association, Stockholm, Sweden (2008) 45:Abs MP375.
57. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA et al: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 361(25):2436-2448.
58. Galenica AG: Galenica Group increases profits by more than 40%. Press Release (2009): March 17.
59. Lyseng-Williamson KA, Keating GM: Ferric carboxymaltose: A review of its use in iron-deficiency anaemia. Drugs (2009) 69(6):739-756.
60. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ: Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol (2008) 19(8):1599-1605.
61. Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ: Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol (2009) 4(2): 386-393.
62. Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L: Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis (2008) 52(5):907-915.
63. AMAG Pharmaceuticals Inc: AMAG Pharmaceuticals announces U.S. launch of Feraheme (ferumoxytol) injection. Press Release (2009): July 14.
64. Wikstrom B, Bhandari S, Barany P, Kalra PA, Ladefoged S, Wilske J, Thomsen LL: Monofer (iron isomaltoside 1000), a novel intravenous iron for treatment of iron deficiency in chronic kidney disease (CKD) patients. Transfus Altern Transf Med (2010) 11(S2):14-40.
65. Hildebrandt P, Bruun NE, Nielsen OW, Pantev E, Shiva F, Videbaek L, Wikstrom G, Thomsen LL: Intravenous iron supplementation with Monofer improved quality of life assessments in patients with chronic heart failure. Transfus Altern Transf Med (2010) 11(S2):14-40.
66. Pharmacosmos obtains first marketing authorisations for Monofer: Pharmacosmos A/S, Holbaek, Denmark (2010). www.pharmacosmos.com/media/news/2010/ 2010-01-26-pharmacosmos-first-marketing-authorisations-for-monofer.aspx
67. Qunibi WY, Benjamin J: Safety and tolerability profile of ferric carboxymaltose (FCM), a new high dose IV iron, across ten multi-center clinical trials. Congress of the European Renal Association and the European Dialysis and Transplant Association, Stockholm, Sweden (2008) 45:Abs MP383.
68. Lyseng-Williamson KA, Keating GM: Ferric carboxymaltose: A review of its use in iron-deficiency anaemia. Drugs (2009) 69(6):739-756.
69. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet (2009) 373(9674):1532-1542.
70. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, Wiecek A, Vanholder R, On behalf of the Anaemia Working Group of European Renal Best Practice (ERBP): Target haemoglobin to aim for with erythropoiesis- stimulating agents: A position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Study. Nephrol Dial Transplant (2010): doi:10.1093/ndt/gfq336.